Ocular involvement in MuSK antibody-positive Myasthenia gravis;Okuläre beteiligung bei MuSK-antikörper-positiver Myasthenia gravis

Klinische Monatsblatter fur Augenheilkunde

Volumn 223, Issue 1, 2006, Pages 81-83

  Bau, Viktoria ^a   Hanisch, F ^a   Hain, B ^a   Zierz, S ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Acetylcholine receptor antibody; Antibodies to muscle specific kinase (MuSK); Ocular and generalized myasthenia gravis; Thymectomy

Indexed keywords

ANTIBODY; AZATHIOPRINE; CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR ANTIBODY; METHYLPREDNISOLONE; MUSCLE SPECIFIC RECEPTOR TYROSINE KINASE; MUSCLE SPECIFIC RECEPTOR TYROSINE KINASE ANTIBODY; PREDNISOLONE; PROTEIN TYROSINE KINASE; PYRIDOSTIGMINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; DIPLOPIA; DISEASE DURATION; DRUG INDICATION; DYSPHAGIA; ENZYME SPECIFICITY; EYE DISEASE; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIMB WEAKNESS; MYASTHENIA GRAVIS; PLASMAPHERESIS; PTOSIS; RESPIRATORY FAILURE; SEROLOGY; SYMPTOMATOLOGY;

ADULT; AUTOANTIBODIES; AUTOIMMUNE DISEASES; AZATHIOPRINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; METHYLPREDNISOLONE; MIDDLE AGED; MYASTHENIA GRAVIS; PREDNISOLONE; PYRIDOSTIGMINE BROMIDE; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, CHOLINERGIC;

EID: 31544453858     PISSN: 00232165     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-858629     Document Type: Article

References (11)

1. Evoli A, Tonali PA, Padua L et al. Clinical correlates with anti-MuSK antibodies in generalized myasthenia gravis. Brain 2003; 126: 1-8
2. Grob D. Natural history of myasthenia gravis. In: Engel AG (Hrsg). Myasthenia gravis and myasthanic disorders. Oxford: Oxford University Press, 1999: 131-145
3. Guillermo GR, Tellez-Zenteno JF, Weder-Cisneros N et al. Response of thymectomy: Clinical and pathological characteristics among seronegative and seropositive myasthenia gravis patients. Acta Neurol Scand 2004; 109: 217-221
4. Kupersmith MJ, Latkany R, Homel P. Development of generalized disease at 2 years in patients with ocular myasthenia gravis. Arch Neurol 2003; 60: 243-248
5. McConville J, Farrugia ME, Beeson D et al. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol 2004; 55: 580-584
6. Mee J, Paine M, Byrne E et al. Immuntherapy of ocular myasthenia gravis reduces conversion to generalized myasthenia gravis. J Neuroophthalmol 2003; 23: 251-255
7. Monsul NT, Patwa HS, Knorr AM et al. The effect of prednisolone on the progression from ocular to generalized myasthenia gravis. J Neurol Sci 2004; 217: 131-133
8. Ohta K, Shigemoto K, Kubo S et al. MuSK antibodies in AChR Ab-seropositive MG vs AChR Ab-seronegative MG. Neurology 2004; 62: 2132-2133
9. Sanders DB, El-Salem K, Massey JM et al. Clinical aspects of MuSK antibody positive seronegative MG. Neurology 2003; 60: 1978-1980
10. Vincent A, Bowen J, Newsom-Davis J et al. Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets. Lancet Neurology 2003; 2: 99-106
11. Zhou L, McConville J, Chaudry V et al. Clinical comparison of muscle-specific tyrosine kinase (MuSK) antibody-positive and -negative myasthenic patients. Muscle Nerve 2004; 30: 55-60